(4) The potential success of PAD4 deficiency and PAD inhibitors in treating experimental arthritis may be misinterpreted as in vivo evidence that NETosis is relevant for RA, while this effect may result from transcriptional repression of immune effector functions or inhibition of LTH. The gene discussed is PADI4; the disease is rheumatoid arthritis.